

---

# Technology review: High-Intensity Focused Ultrasound for prostate cancer

Tom Pickles, MD,<sup>1</sup> S. Larry Goldenberg, MD,<sup>2</sup> Gary Steinhoff, MD<sup>1</sup>

<sup>1</sup>BC Cancer Agency, Vancouver, BC, Canada

<sup>2</sup>The Prostate Centre, Vancouver General Hospital, Vancouver, BC, Canada

---

PICKLES T, GOLDENBERG SL, STEINHOFF G. Technology review: High-Intensity Focused Ultrasound for prostate cancer. *The Canadian Journal of Urology*. 2005;12(2):2593-2597.

**Introduction and objective:** High-Intensity Focused Ultrasound (HIFU) is a technology that has moved from being used for benign prostate disease to the treatment of prostate cancer. A technology review was undertaken to guide patients and physicians as to its suitability.

**Method:** An evidence-based review of published papers in the English language, with additional material from internet and other sources.

**Results and conclusions:** Only case series have been published; there are no randomized studies. The quality of evidence is poor, with no reports having longer follow-

up than a mean of 2 years, with median follow-ups substantially shorter. Efficacy outcomes are thus premature and preclude assessment. Toxicity varies substantially with impotence rates 44%-61%, grade 2-3 incontinence 0%-14%, and rectal fistulae 0.7%-3.2%. There is limited data on the use of HIFU for the salvage therapy after radiation failure. There are no data on the toxicity of subsequent standard curative therapies after HIFU.

In view of the lack of efficacy outcomes, and in the presence of significant toxicity, HIFU should only be offered within a research setting.

**Key Words:** prostate cancer, randomized controlled trial, trial participation, cryotherapy, decision-making

---

## Background

High-Intensity Focused Ultrasound (HIFU) is a technique using focused ultrasound to generate areas of intense heat and thus destroy tissue. It has been studied for 50 years, with recent technological developments allowing its use for tumors of liver, prostate and other sites.<sup>1</sup> It is increasingly being

promoted as a non-invasive therapy for localized prostate cancer, and is generally regarded as experimental by independent authorities<sup>2</sup> because no randomized data exists to support its use and duration of follow-up from case series is short. It is being promoted particularly by the companies that make the equipment, eg Focus Surgery Inc who market the Sonablate® device, and EDAP who make the Ablatherm® device.<sup>3</sup> EDAP is dependent on the successful development and commercialization of its HIFU medical devices to achieve and sustain profitability in the future. The Sonablate device is not licensed for use in Canada, but the Ablatherm device is approved for commercial distribution in

---

Accepted for publication March 2005

Address correspondence to Dr. Tom Pickles, BC Cancer Agency, 600 West 10<sup>th</sup> Avenue, Vancouver BC V6R 2T9 Canada

Canada, the European Union, South Korea and Russia, but neither has gained FDA approval. Eighteen Ablatherm machines worldwide through 44 clinical sites treated 1477 patients using this technology in 2003.<sup>4</sup>

## Methodology

A Medline, Embase, Medline In-Process and Daily Updates search was undertaken in December 2004 for relevant peer reviewed English language articles. Search terms used were "ultrasound ablation.tw.", "high intensity focused ultrasound.tw.", "HIFU.ti.", "(HIFU and prostate).tw.". Additional information was gleaned from internet searches, and from papers cited in those papers initially reviewed.

## Existing overviews

The UK's National Centre for Clinical Excellence (NICE) has produced a detailed overview of the recent literature (up to March 2004),<sup>5</sup> which is partly based on a review carried out in the UK the previous year.<sup>2</sup> The NICE process for evaluation is currently (February 2005) ongoing and a final report has not yet been issued. Interested readers are encouraged to read their report.

## Quality of the evidence

No randomized studies have been carried out, and there are only case-series reported with a total of approximately 600 patients. It is difficult to determine the true total because many are duplicates reported in different publications. The completeness of follow-up is not documented. This may be an issue where a treatment is only available in a few centres and patients travel long distances. Some papers on HIFU are authored by those who hold patents for the device or participate in company advisory boards.

An additional consideration is that techniques have changed as experience has been gained. In particular there have been hardware and software changes since 2000 which apparently have reduced toxicity. Therefore those patients with the most follow-up were treated with techniques that are no longer in use, and those treated with newer techniques have shorter follow-up, which may further limit conclusions regarding efficacy and longer-term toxicity. It is noteworthy that most reports quote mean rather than median follow-up, which may be inappropriate where the majority of patients have only recently been treated.

## Modern technique and patient selection

Patients treated with HIFU generally have low to intermediate risk prostate cancer. For definitions see.<sup>6</sup>

The learning curve is well described by Chaussy,<sup>7</sup> who suggests that the learning curve using the Ablatherm equipment is as short as 10 patients for a new user with technical skills in ultrasound imaging. Technical enhancements include routine pre-HIFU TURP in those with obstructive symptoms, the use of prophylactic antibiotics, leaving a 5 mm margin around the prostate apex untreated (although the heat dissipates further than the ultrasound 'shot'), rectal cooling, and the use of higher frequency transducers (3MHz).

Patients are generally treated under spinal anesthesia. If a pre-HIFU TURP is performed then it is typically carried out at the same time, and necessitates a short hospital stay.<sup>8</sup> The overall treatment time is 2-3 hours.<sup>1</sup>

### *Patient selection*

In the absence of efficacy data (*vide infra*) it is difficult to determine those who may benefit from HIFU. However, extrapolating from radiation and surgical outcomes data we can predict that those patients with a significant risk of extra-capsular extension (ECE) of tumor are likely unsuitable for HIFU. This is because the volume of tissue destruction is designed not to extend beyond the prostate capsule (and in some cases may purposefully or accidentally be less than total prostate ablation).

The probability of ECE may be predicted from the Kattan nomogram,<sup>9</sup> which is based on the Partin surgical series.<sup>10</sup> Patients with initial PSA > 10ng/ml, who otherwise have good prognosis tumors have a 30% risk of ECE, patients with Gleason 7 cancer, irrespective of PSA have a >30% ECE risk, as do patients with clinical T2a disease, irrespective of PSA or Gleason score. Recent data with percent positive cores (PPC) additionally suggest that those with greater than 50% PPC carry a significantly worse prognosis – even within the low and intermediate risk group.<sup>11</sup> The remaining patients (those with T1c, initial PSA < 10, Gleason score 6 or less, and less than 50% PPC) represent a favorable group of patients who have excellent outcomes irrespective of treatment, and indeed may not require any intervention at all.

In terms of potential toxicity and other technical considerations, case series suggest the following selection criteria. This list is not intended to be a

## Technology review: High-Intensity Focused Ultrasound for prostate cancer

complete guide of patient exclusions:

- Prostate volume <30 cc<sup>7</sup> – 50 cc<sup>12</sup> (if necessary after neoadjuvant androgen ablation downsizing)
- No calcification >5 mm (unless removed by TURP first)<sup>7</sup>
- Normal rectal anatomy

### Toxicity

Table 1 summarizes toxicity rates from recent series using modern techniques. Rectal fistula appears to be the most serious potential complication. Rectal cooling may reduce this risk,<sup>13</sup> as may decreasing the posterior treatment margin (at a risk of leaving a posterior rim of tissue unaffected<sup>16</sup>). Fistulae are much commoner in men who were treated with HIFU following radiation failure.<sup>14,17</sup> Because of the short distance from prostate capsule to rectal mucosa, complete ablation of tumors that are located in the posterior-peripheral region may be problematic. Unfortunately this is exactly the commonest location

for extension of prostate cancer radially beyond the capsule.<sup>18</sup> Patients with abnormal rectal anatomy and thick rectal walls >6 mm<sup>19</sup> are excluded from therapy.

### Efficacy

A histopathologic study where patients underwent HIFU, followed 1-2 weeks later by radical prostatectomy revealed incomplete HIFU-lesions at the ventral, lateral, and dorsal sides of the prostate lobe treated, and some prostate glands without apparently necrotic features situated within the HIFU lesions, raising the question of whether lethal destruction had occurred.<sup>20</sup> The extent to which technological enhancements to the treatment algorithm may overcome the concerns of the authors<sup>16</sup> is uncertain.

Evaluation of efficacy is particularly difficult given the long natural history of both treated and untreated prostate cancer. End points generally used have been biopsy and/or PSA based. A confounder is the use of

TABLE 1. Early and late toxicity

		Number of patients (n)	Reference
<b>Early toxicity</b>			
Duration of suprapubic catheter	12.7 days mean	137	12
	32 days mean	218	13
	40 days median HIFU-only,	96	8
	7 days pre-HIFU TURP group	175	
Urinary tract infection	48% HIFU-only,	96	8
	11.4% pre-HIFU TURP	175	
IPSS score pre-post (mean)	6.5 – 8.9 HIFU-only,	96	8
	6.7 – 3.4 pre-HIFU TURP	175	
<b>Late toxicity</b>			
Recto-urethral fistula	%	<b>n, mean follow-up</b>	<b>Reference</b>
	0.7%	137, 22 months	12
	3.2%	62, 15 months median	14
Chronic pelvic pain	1%	102, 19 months	15
	1.5%	137, 22 months	12
Post-HIFU TURP rate	11.7%	137, 22 months	12
	30%	218, not stated	13
	27% HIFU-only,	96, 18.7 months	8
	8% pre-HIFU TURP group	175, 10.9 months	
Grade 2-3 incontinence	32%	62, 15 months median	14
	0%	137, 22 months	12
	14%	102, 19 months	15
Impotence, of those potent prior	4.8%	62, 15 months median	14
	57.7%	137, 22 months	12
	61%	102, 19 months	15
	44.4%	62, 15 months median	14

neoadjuvant androgen deprivation therapy (ADT), which is used in 40%-44% of HIFU patients.<sup>7,12</sup> Even a single injection of an LHRH can lead to delayed testosterone recovery. BC data<sup>21</sup> suggests the median time to recovery of testosterone to a level of 50% of normal takes an additional 10 months after the date the drug is meant to have worn off. This is similar to the mean follow-up in the case series, which averages 14 months. There are no published case reports with longer mean follow-up than 2 years. The quality/completeness of follow-up has not been reported, and as HIFU is only available in a limited number of centres it is supposed that close follow-up has been problematic given the large distances many patients will have traveled for therapy.

### *Biopsy*

Sampling the peripheral parts of the prostate, especially adjacent to the rectum and apex (where HIFU-ablation may have been purposefully avoided) is required and thus biopsies of the other parts of the prostate are less likely to detect residual cancer. The negative biopsy rate after partial and complete prostate treatment are equivalent (92% versus 87%,  $p=0.32$ ,<sup>19</sup> suggesting that sampling may be an underlying problem. The use of neoadjuvant ADT may make interpretation difficult. Negative biopsy rates range from ~60%-80%,<sup>5</sup> but at a short mean follow-up of 14 months.

### *PSA*

Differing definitions of PSA response are used in the reports. PSA nadir may be used as a measure of prostate ablation, but it is uncertain to what extent this correlates with subsequent cure. Alternatively a rising PSA profile may indicate recurrent cancer. There is considerable controversy surrounding what constitutes biochemical relapse after radiation therapy, and there is no literature as to the most appropriate measure after HIFU.

Where follow-up is short, true relapse rates are underestimated because some patients have not yet had sufficient time for the required three rises to occur for the widely-used ASTRO definition.<sup>22</sup> PSA nadir <0.5 ng/ml rates vary from 55% to 83%<sup>5</sup> and PSA control rates (ASTRO definition) vary from 66% to 82% after 3 years follow-up.<sup>8</sup> Patients with larger prostate glands have higher PSA nadir's (2 ng/ml >40 cc, compared with 0.4 ng/ml <40 cc),<sup>19</sup> presumably because it is not possible to ablate all prostate cancer/tissue in those with larger glands. Larger prostate glands (>30 cc) are described as a contraindication to treatment by Chaussy.<sup>7</sup>

For the reasons discussed above we believe that no conclusions can be drawn about the efficacy of treatment, a view shared by the Health Technology Assessment review.<sup>2</sup>

### Re-treatment and tolerance of other therapy

More than one HIFU session was used in the early development of HIFU, particularly where only partial prostate treatment was used. Modern techniques, which employ whole-gland ablation and pre-HIFU TURP, have reduced the need for multiple treatments from 11.4% to 4%.<sup>8</sup>

We were unable to find any detailed data on either tolerance of repeated treatment, or tolerance of subsequent conventional therapy after HIFU failure. A prior TURP (and thus presumably HIFU ablation) sharply increases the risk of incontinence and other GU toxicity after radiation therapy.<sup>23</sup> Brachytherapy would be contraindicated after HIFU. Blana<sup>12</sup> comments that the risk of complications increases with multiple treatments, but does not provide data in support of the statement.

In the absence of data showing that salvage therapy after HIFU is both safe and effective we do not feel it is appropriate to promote HIFU as a measure that can be repeated and /or followed by conventional therapy.

### Treatment of patients with recurrent disease after radiation therapy

Over a 7 year time period, Gelet and colleagues<sup>17</sup> treated 71 patients who had failed external radiation therapy and who were thought to have sole localized recurrence on the basis of positive prostate biopsies. The mean follow-up is short at 15 months, so efficacy results are premature. Actuarial projections of disease-free survival at 2 years were ~42%. The negative biopsy rate was 73%, presumably indicating high rates of failure outside the prostate. As referenced in the paper, the equivalent disease-free control rates with surgery are 43% and 31% with cryotherapy. However these rates were achieved after very much longer follow-up of 10 and 5 years respectively. The importance of patient selection in this group of patients makes comparison between series unwise. A recent review of the role of cryotherapy is referenced for the interested reader.<sup>24</sup>

### Conclusions

Lack of efficacy data does not allow meaningful

## Technology review: High-Intensity Focused Ultrasound for prostate cancer

assessment as to the benefit – risk ratio of HIFU treatment. It would therefore be inappropriate to offer HIFU as standard therapy for prostate cancer. It could be further explored in a phase 1-2 research setting.

Patients who may be suitable for such an experimental protocol include those who are not suitable for established curative therapies of prostate cancer (e.g. radical prostatectomy, brachytherapy and external beam radiation therapy) and those with a pure localized recurrence after radiation therapy. This latter group is particularly at risk of significant long-term complications and the potential benefit of such treatment should be balanced against toxicity, other available options, and the natural history of recurrent prostate cancer. □

---

### References

---

1. Kennedy JE, Ter Haar GR, Cranston D. High intensity focused ultrasound: surgery of the future? *Br J Radiol* 2003;76(909):590-599.
2. Hummel S et al. Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review. HMSO: <http://www.ncchta.org/execsumm/summ733.htm>, 2003;7(33):21-22.
3. Ablatherm [http://www.edap-hifu.com/eng/physicians/hifu/3a\\_treatment\\_overview.htm](http://www.edap-hifu.com/eng/physicians/hifu/3a_treatment_overview.htm).
4. EDAP Annual Report 2003, [http://www.edaptechnomed.com/eng/images/annual\\_report\\_2003.pdf](http://www.edaptechnomed.com/eng/images/annual_report_2003.pdf).
5. National Institute for Clinical Excellence. High-intensity focused ultrasound for prostate cancer. <http://www.nice.org.uk/page.aspx?o=80298>, 2004.
6. Lukka H et al. Controversies in prostate cancer radiotherapy: consensus development. *Can J Urol* 2001;8(4):1314-1322.
7. Chaussy C, Thuroff S. High-intensity focused ultrasound in prostate cancer: results after 3 years. *Molecular Urology* 2000;4(3):179-182.
8. Chaussy C, Thuroff S. The status of high-intensity focused ultrasound in the treatment of localized prostate cancer and the impact of a combined resection. *Curr Urol Rep* 2003;4(3):248-252.
9. Kattan M, *Prostogram*. <http://www.nomograms.org>, 2002.
10. Partin AW et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. *JAMA* 1997;277(18):1445-1451.
11. D'Amico AV et al. Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk disease. *J Clin Oncol* 2004;22(18):3726-3732.
12. Blana A et al. High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience. *Urology* 2004;63(2):297-300.
13. Thuroff S. et al. High-intensity focused ultrasound: Complications and adverse events. *Molecular Urology* 2000;4(3):2000.
14. Kiel HJ, Wieland WF, Rossler W. Local control of prostate cancer by transrectal HIFU-therapy. *Archivio Italiano di Urologia, Andrologia* 2000;72(4):313-319.
15. Gelet A et al. Transrectal high intensity focused ultrasound for the treatment of localized prostate cancer: factors influencing the outcome. *Eur Urol* 2001;40(2):124-129.
16. Beerlage HP et al. High-intensity focused ultrasound (HIFU) followed after one to two weeks by radical retropubic prostatectomy: results of a prospective study. *Prostate* 1999;39(1):41-46.
17. Gelet A et al. Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography. *Urology* 2004;63(4):625-629.
18. Davis BJ et al. The radial distance of extraprostatic extension of prostate carcinoma: implications for prostate brachytherapy. *Cancer* 1999;85(12):2630-2637.
19. Thuroff S et al. High-intensity focused ultrasound and localized prostate cancer: efficacy results from the European multicentric study. *J Endourol* 2003;17(8):673-677.
20. Van Leenders GJ et al. Histopathological changes associated with high intensity focused ultrasound (HIFU) treatment for localised adenocarcinoma of the prostate. *Journal of Clinical Pathology* 2000;53(5):391-394.
21. Pickles T et al. Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma. *Cancer* 2002;94(2):362-367.
22. Vicini FA, Kestin LL, Martinez AA. The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer. *Int J Radiat Oncol Biol Phys* 1999;45(3):553-561.
23. Liu M et al. Impact of Pre-Radiotherapy TURP on Late Genitourinary Toxicity for Prostate Cancer Patients Undergoing External Radiation Therapy in Canadian Association Radiation Oncologists. 2003. Montreal: Radiotherapy & Oncology.
24. Rees J et al. Cryosurgery for prostate cancer. *BJU Int* 2004;93(6):710-714.